Table 2.
Factors associated with having either significant hepatic fibrosis or cirrhosis, based on the AST-to-platelet ratio index, at ART initiation in Zambia
| APRI ≥1.5 (Significant fibrosis) | Crude OR (95% CI) |
Adjuste OR (95% CI) |
|---|---|---|
| Age, per 10-year increase | 1.03 (0.97–1.10) | 0.95 (0.88–1.03) |
| Male sex | 2.22 (1.96–2.52) | 1.98 (1.72–2.28) |
| BMI | ||
| >25 | Reference | Reference |
| 18–25 | 1.93 (1.40–2.66) | 1.25 (0.90–1.74) |
| <18 | 3.21 (2.32–4.44) | 1.41 (1.00–1.99) |
| WHO clinical stage 3 or 4 | 2.50 (2.12–2.93) | 1.82 (1.52–2.18) |
| Tuberculosis | 1.71 (1.48–1.99) | 1.20 (1.02–1.41) |
| CD4+ count, cells/mm3 | ||
| >200 | Reference | Reference |
| 100–200 | 1.87 (1.52–2.29) | 1.84 (1.49–2.27) |
| <100 | 4.03 (3.36–4.85) | 3.44 (2.84–4.18) |
| APRI ≥ 2.0 (Cirrhosis)
| ||
| Age, per 10-year increase | 0.98 (0.89–1.07) | 0.89 (0.81–0.99) |
| Male sex | 2.22 (1.89–2.61) | 2.04 (1.70–2.43) |
| BMI | ||
| >25 | Reference | Reference |
| 18–25 | 1.95 (1.27–2.98) | 1.26 (0.81–1.97) |
| <18 | 3.67 (2.39–5.63) | 1.59 (1.01–2.50) |
| WHO clinical stage 3 or 4 | 2.50 (2.03–3.07) | 1.76 (1.39–2.22) |
| Tuberculosis | 1.82 (1.51–2.19) | 1.26 (1.03–1.55) |
| CD4+ count, cells/mm3 | ||
| >200 | Reference | Reference |
| 100–200 | 1.91 (1.46–2.50) | 1.87 (1.42–2.46) |
| <100 | 4.28 (3.37–5.45) | 3.47 (2.70–4.46) |
Abbreviations: AST, aspartate aminotransferase; ART, antiretroviral therapy; OR, odds ratio; BMI, body mass index; WHO, World Health Organization